In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Cardiff Oncology, with a price target of $10.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Robert Burns has given his Buy rating due to a combination of factors related to Cardiff Oncology’s recent clinical trial results and financial performance. The CRDF-004 trial data indicates that the combination of onvansertib with standard of care (SoC) achieved a higher confirmed overall response rate compared to the SoC alone, demonstrating promising efficacy despite a decline from initial results. Additionally, the unconfirmed response rate shows potential for further positive outcomes.
Cardiff’s financial results for the third quarter of 2025 showed a net loss per share that was better than anticipated, and the company maintains a strong cash position, which is expected to support operations into early 2027. The valuation of Cardiff Oncology is based on a discounted cash flow model, with a price target of $10 per share. However, risks such as potential negative trial results, delays in clinical advancements, and market penetration challenges are noted, but the overall outlook remains positive, justifying the Buy rating.
Burns covers the Healthcare sector, focusing on stocks such as Replimune Group, Cullinan Management, and Bicara Therapeutics Inc.. According to TipRanks, Burns has an average return of -2.6% and a 41.25% success rate on recommended stocks.